Finch Therapeutics Announces Executive Leadership Transitions
25 avr. 2023 16h05 HE
|
Finch Therapeutics Group, Inc.
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO...
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
25 avr. 2023 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
18 avr. 2023 16h01 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Verb Biotics announces participation in Ginkgo Bioworks’ annual Ferment conference
18 avr. 2023 11h25 HE
|
Verb Biotics
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Verb Biotics, a microbiome innovation company, today announced that it will be participating as a next-generation biotech innovator at Ferment, Ginkgo...
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
04 avr. 2023 08h00 HE
|
Axial Therapeutics
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...
Global Gut Microbiome Growth Opportunities 2023: Targeted Gut Microbiome Technologies to Drive Transformational Growth Across the Global Healthcare Landscape
03 avr. 2023 05h33 HE
|
Research and Markets
Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "Global Gut Microbiome Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study identifies and analyzes research...
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
30 mars 2023 03h00 HE
|
Trobix Bio
Netanya, Israel, March 30, 2023 - Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announced today the...
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
29 mars 2023 08h00 HE
|
Axial Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
28 mars 2023 03h00 HE
|
EnteroBiotix
GLASGOW, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome...
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
23 mars 2023 16h05 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...